

OBLON SPIVAK

McClelland

MAIER

NEUSTADT

P.C.

ATTORNEYS AT LAW

Docket No.: 210229US0PCT

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

RE: Patent No.:

7,060,721

Applicants: Teruo OKU, et al.

Issue Date:

June 13, 2006

For: IMIDAZOLE COMPOUNDS AND MEDICINAL USE

THEREOF Group Art Unit: 1626

Examiner: Laura L. STOCKTON

SIR:

Attached hereto for filing are the following papers:

PETITION FOR CERTIFICATE OF CORRECTION UNDER 37 CFR § 1.183

Our credit card payment form in the amount of \$500.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 50,238

Joseph Scafetta, Jr.

Registration No. 26.803

Customer Number

22850

(703) 413-3000 (phone) (703) 413-2220 (fax)

DOCKET NO.: 210229US0PC

IN THE UNITED STATES PARENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Teruo OKU, et al.

PATENT NO.: 7,060,721

GROUP: 1626

ISSUED: June 13, 2006

EXAMINER: Laura L. STOCKTON

FOR: IMIDAZOLE COMPOUNDS AND MEDICINAL USE THEREOF

PETITION FOR CERTIFICATE OF CORRECTION UNDER 37 CFR § 1.183

DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE ALEXANDRIA, VA 22313-1450

SIR:

We respectfully request the requirements of 37 CFR 3.81 be waived to permit the correct name of the assignee be provided after issuance of the patent.

An assignment transferring all rights from the inventors to Fujisawa Pharmaceutical Co., Ltd. was recorded at Reel/Frame 012660/0704 on February 27, 2002, in the above-identified Patent. Further, an assignment transferring all rights from Fujisawa Pharmaceutical Co., Ltd. to Astellas Pharma Inc. was recorded at Reel/Frame 017073/0257 on December 12, 2005.

When submitting the PTOL-85b at the time of payment of the Issue Fee, a clerical error occurred and Fujisawa Pharmaceutical Co., Ltd. was inadvertently listed as the assignee.

In accordance with the provisions of Rule 323 of the Rules of Practice, which implement 35 USC 255, the Patent Office is respectfully requested to issue a certificate of correction to indicate the correct Assignee as Astellas Pharma Inc.

We are enclosing a credit card payment form in the amount of \$500.00 (\$400.00 to cover the petition fee and \$100.00 for the Certificate of Correction). The requested corrections are listed on FORM P.T.O. 1050.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 Stefan U. Koshmieder, Ph.D.

Registration No. 50,238

Joseph Scafetta, Jr. Registration No. 26,803

07/03/2006 SZEWDIE1 00000047 7060721

01 FC:1462 02 FC:1811 400.00 OP 100.00 OP UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO.:

7,060,721

DATED:

Jun. 13, 2006

INVENTOR(S):

Oku et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page, Item (73), the Assignee information is incorrect. Item (73) should read:

-- (73) Assignee: Astellas Pharma Inc., Tokyo (JP) --

Mailing address of sender:

Patent No.

7,060,721

Customer Number

No. of add'l copies @ .30 per page

22850

口〉

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 03/02)